

us-09-254-760a-9.rapm

0:27:37 2002

Fri Jul

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1

Sequence 4474, Appl1











Accession	AF052775	Version	1	GI:4779196
Source	Human	Organism	Homo sapiens	
Reference	Thompson, D.A. and Wajsbol, R.J. 1997. The human homologue of the Xenopus laevis c-myc oncogene is expressed with estrogen receptor in breast cancer cell lines. <i>Biochem. Biophys. Res. Commun.</i> 231: 111-116 (1997).	Journal	Journal of Cellular Biochemistry	Volume 64, Pages 111-116
Keywords	Estrogen Receptor, c-myc, Breast Cancer, Human	Keywords	Estrogen Receptor, c-myc, Breast Cancer, Human	
Abstract	The human homologue of the Xenopus laevis c-myc oncogene is expressed with estrogen receptor in breast cancer cell lines. <i>Biochem. Biophys. Res. Commun.</i> 231: 111-116 (1997).	Abstract	The human homologue of the Xenopus laevis c-myc oncogene is expressed with estrogen receptor in breast cancer cell lines. <i>Biochem. Biophys. Res. Commun.</i> 231: 111-116 (1997).	
Sequence	1-838	Sequence	1-838	
Source	Human	Source	Human	
Accession	AF052775	Version	1	GI:4779196
Source	Human	Organism	Homo sapiens	
Reference	Thompson, D.A. and Wajsbol, R.J. 1997. The human homologue of the Xenopus laevis c-myc oncogene is expressed with estrogen receptor in breast cancer cell lines. <i>Biochem. Biophys. Res. Commun.</i> 231: 111-116 (1997).	Journal	Journal of Cellular Biochemistry	Volume 64, Pages 111-116
Keywords	Estrogen Receptor, c-myc, Breast Cancer, Human	Keywords	Estrogen Receptor, c-myc, Breast Cancer, Human	
Abstract	The human homologue of the Xenopus laevis c-myc oncogene is expressed with estrogen receptor in breast cancer cell lines. <i>Biochem. Biophys. Res. Commun.</i> 231: 111-116 (1997).	Abstract	The human homologue of the Xenopus laevis c-myc oncogene is expressed with estrogen receptor in breast cancer cell lines. <i>Biochem. Biophys. Res. Commun.</i> 231: 111-116 (1997).	
Sequence	1-838	Sequence	1-838	
Source	Human	Source	Human	



















360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596  
 597  
 598  
 599  
 600  
 601  
 602  
 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683  
 684  
 685  
 686  
 687  
 688  
 689  
 690  
 691  
 692  
 693  
 694  
 695  
 696  
 697  
 698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714  
 715  
 716  
 717  
 718  
 719  
 720  
 721  
 722  
 723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731  
 732  
 733  
 734  
 735  
 736  
 737  
 738  
 739  
 740  
 741  
 742  
 743  
 744  
 745  
 746  
 747  
 748  
 749  
 750  
 751  
 752  
 753  
 754  
 755  
 756  
 757  
 758  
 759  
 760  
 761  
 762  
 763  
 764  
 765  
 766  
 767  
 768  
 769  
 770  
 771  
 772  
 773  
 774  
 775  
 776  
 777  
 778  
 779  
 780  
 781  
 782  
 783  
 784  
 785  
 786  
 787  
 788  
 789  
 790  
 791  
 792  
 793  
 794  
 795  
 796  
 797  
 798  
 799  
 800  
 801  
 802  
 803  
 804  
 805  
 806  
 807  
 808  
 809  
 810  
 811  
 812  
 813  
 814  
 815  
 816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829  
 830  
 831  
 832  
 833  
 834  
 835  
 836  
 837  
 838  
 839  
 840  
 841  
 842  
 843  
 844  
 845  
 846  
 847  
 848  
 849  
 850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864  
 865  
 866  
 867  
 868  
 869  
 870  
 871

[illegible]

RESULT	4
AAZ52865	
11D	AAZ52865 standard; cDNA; 1,625 bp.
XX	
XX	AAZ52865;
XX	
XX	14-MAR-2000 (first entry)
XX	
XX	Human prostate tumor cDNA library derived from 125T irradiated
DE	
XX	Pancreas; tumor; EST; expressed sequences from Japanese
KW	treatment; ds.
KW	
XX	
XX	Homo sapiens.
OS	
XX	DEF1962337 AL1.
XX	
XX	04-NOV-1999.
ED	
XX	
XX	26-APR-1998; GDBE-142014.
TF	
XX	
XX	28-APR-1998; GDBE-142014.
PR	
XX	
XX	(MELAS) GENBANK GENBANK:U00007.M86
EA	
XX	
XX	Rogen,thal A. Spectral, Hingman, B. Sediment, A. F. 1978
PL	
XX	
XX	WPI: 1999-62386/64.
PR	
XX	EST: AA173619, AA173846, AA173852.







1000 bp, but additional probes are also useful for identification. The region shown represents cDNA encoding

[illegible]

99.78;	Score	100.0;	LB	22;	Length	875;
99.86;	Prod. N	100.0;	LB	12;		
99.91	Prod. N	100.0;	LB	1;	Indels	0;
99.91	Prod. N	100.0;	LB	1;	Gaps	0;

intensity of calcium light is not different between the two groups 60

**Abstract**

[illegible][illegible][illegible]

bioRxiv preprint doi: <https://doi.org/10.1101/2019.04.10.332011>; this version posted April 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

... .. 370

.....

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

[illegible][illegible]

hormone-mediated tumorigenesis; tumour metastasis;

respiratory disease; 1.1, inflammatory bowel disease; bronchitis

Fig. 1.  $\Delta$  = 1000;  $\Delta$  = 100;  $\Delta$  = 10;  $\Delta$  = 1;  $\Delta$  = 0.5;  $\Delta$  = 0.25;  $\Delta$  = 0.125;  $\Delta$  = 0.0625;  $\Delta$  = 0.03125;  $\Delta$  = 0.015625;  $\Delta$  = 0.0078125;  $\Delta$  = 0.00390625;  $\Delta$  = 0.001953125;  $\Delta$  = 0.0009765625;  $\Delta$  = 0.00048828125;  $\Delta$  = 0.000244140625;  $\Delta$  = 0.0001220703125;  $\Delta$  = 0.00006103515625;  $\Delta$  = 0.000030517578125;  $\Delta$  = 0.0000152587890625;  $\Delta$  = 0.00000762939453125;  $\Delta$  = 0.000003814697265625;  $\Delta$  = 0.0000019073486328125;  $\Delta$  = 0.00000095367431640625;  $\Delta$  = 0.000000476837158203125;  $\Delta$  = 0.0000002384185791015625;  $\Delta$  = 0.00000011920928955078125;  $\Delta$  = 0.000000059604644775390625;  $\Delta$  = 0.0000000298023223876953125;  $\Delta$  = 0.00000001490116119384765625;  $\Delta$  = 0.000000007450580596923828125;  $\Delta$  = 0.0000000037252902984619140625;  $\Delta$  = 0.00000000186264514923095703125;  $\Delta$  = 0.000000000931322574615478515625;  $\Delta$  = 0.0000000004656612873077392578125;  $\Delta$  = 0.00000000023283064365386962890625;  $\Delta$  = 0.000000000116415321826934814453125;  $\Delta$  = 0.0000000000582076609134674072265625;  $\Delta$  = 0.00000000002910383045673370361328125;  $\Delta$  = 0.000000000014551915228366851806640625;  $\Delta$  = 0.0000000000072759576141834259033203125;  $\Delta$  = 0.00000000000363797880709171295166015625;  $\Delta$  = 0.000000000001818989403545856475830078125;  $\Delta$  = 0.0000000000009094947017729282379150390625;  $\Delta$  = 0.00000000000045474735088646411895751953125;  $\Delta$  = 0.000000000000227373675443232059478759765625;  $\Delta$  = 0.0000000000001136868377216160297393798828125;  $\Delta$  = 0.00000000000005684341886080801486968994140625;  $\Delta$  = 0.000000000000028421709430404007434844970703125;  $\Delta$  = 0.0000000000000142108547152020037174224853515625;  $\Delta$  = 0.00000000000000710542735760100185871124267578125;  $\Delta$  = 0.000000000000003552713678800500929355621337890625;  $\Delta$  = 0.0000000000000017763568394002504646778106689453125;  $\Delta$  = 0.00000000000000088817841970012523233890533447265625;  $\Delta$  = 0.000000000000000444089209850062616169452667236328125;  $\Delta$  = 0.0000000000000002220446049250313080847263336181640625;  $\Delta$  = 0.00000000000000011102230246251565404236316680908203125;  $\Delta$  = 0.000000000000000055511151231257827021181583404541015625;  $\Delta$  = 0.0000000000000000277555756156289135105907917022705078125;  $\Delta$  = 0.00000000000000001387778780781445675529539585113525390625;  $\Delta$  = 0.000000000000000006938893903907227877647697925567626953125;  $\Delta$  = 0.0000000000000000034694469519536139388238489627838134765625;  $\Delta$  = 0.00000000000000000173472347597680696941192448139190673828125;  $\Delta$  = 0.000000000000000000867361737988403484705962240695953369140625;  $\Delta$  = 0.0000000000000000004336808689942017423529811203479766845703125;  $\Delta$  = 0.00000000000000000021684043449710087117649056017398834228515625;  $\Delta$  = 0.000000000000000000108420217248550435588245280086994171142578125;  $\Delta$  = 0.0000000000000000000542101086242752177941226400434970855712890625;  $\Delta$  = 0.00000000000000000002710505431213760889706132002174854278564453125;  $\Delta$  = 0.000000000000000000013552527156068804448530660010874271392822265625;  $\Delta$  = 0.0000000000000000000067762635780344022242653300054371356964111328125;  $\Delta$  = 0.00000000000000000000338813178901720111213266500271856784820556640625;  $\Delta$  = 0.000000000000000000001694065894508600556066332501359283924102783203125;  $\Delta$  = 0.0000000000000000000008470329472543002780331662506796419620513916015625;  $\Delta$  = 0.00000000000000000000042351647362715013901658312533982098102569580078125;  $\Delta$  = 0.000000000000000000000211758236813575069508291562669910490512847900390625;  $\Delta$  = 0.0000000000000000000001058791184067875347541457813349552452564239501953125;  $\Delta$  = 0.00000000000000000000005293955920339376737707289066747762262821197509765625;  $\Delta$  = 0.000000000000000000000026469779601696883688536445333738811314105987548828125;  $\Delta$  = 0.0000000000000000000000132348898008484418442682226668694056570529937744140625;  $\Delta$  = 0.00000000000000000000000661744490042422092213411133343470282852649688720703125;  $\Delta$  = 0.000000000000000000000003308722450212110461067055666717351414263248443603515625;  $\Delta$  = 0.00000000000











07 421 at east qaadaatatafcaaaacaaatctctatagcttacaqaacctacaaatacaaaatctctgtttg 480  
bb 475 afccaaqaataatfcaaaacaaatctctatagcttacaqaacctacaaatacaaaatctctgtttg 532  
07 481 cttaqaacaaatqaadaaaatctctcaaatctgtctaaada 517  
bb 533 cttaqaa -caatqaadaaactctcaaatctgtctaaada 567

Search completed: July 19, 2002, 03:48:57  
Job time: 10519 sec

us-09-254-760a-18.rni

10:27:32 2002

Fri

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993

Sequence 1, Appl 1, 1993



















100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

10:27:32 2002

Fri

Copyright (c) 1999 by American Express Company

Search using 800000

City of 2002, 00:00:00 Search time 4784.41 seconds  
(without alignments)  
254 077 Million cell updates/sec

us-09-254-760a-18

Search using 800000

us-09-254-760a-18

Search using 800000

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

us-09-254-760a-18

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being analyzed, and is derived by analysis of the total score distribution.

SUMMARY

Result No.	Query	Score	Match Length	LR	Description
1	100.0	925	24	18	Sequence 100.0, 18
2	100.0	925	24	18	Sequence 100.0, 18
3	100.0	925	24	18	Sequence 100.0, 18
4	100.0	925	24	18	Sequence 100.0, 18
5	100.0	925	24	18	Sequence 100.0, 18
6	100.0	925	24	18	Sequence 100.0, 18
7	100.0	925	24	18	Sequence 100.0, 18
8	100.0	925	24	18	Sequence 100.0, 18
9	100.0	925	24	18	Sequence 100.0, 18
10	100.0	925	24	18	Sequence 100.0, 18
11	100.0	925	24	18	Sequence 100.0, 18
12	100.0	925	24	18	Sequence 100.0, 18
13	100.0	925	24	18	Sequence 100.0, 18
14	100.0	925	24	18	Sequence 100.0, 18
15	100.0	925	24	18	Sequence 100.0, 18
16	100.0	925	24	18	Sequence 100.0, 18
17	100.0	925	24	18	Sequence 100.0, 18
18	100.0	925	24	18	Sequence 100.0, 18
19	100.0	925	24	18	Sequence 100.0, 18
20	100.0	925	24	18	Sequence 100.0, 18
21	100.0	925	24	18	Sequence 100.0, 18
22	100.0	925	24	18	Sequence 100.0, 18
23	100.0	925	24	18	Sequence 100.0, 18
24	100.0	925	24	18	Sequence 100.0, 18
25	100.0	925	24	18	Sequence 100.0, 18
26	100.0	925	24	18	Sequence 100.0, 18
27	100.0	925	24	18	Sequence 100.0, 18
28	100.0	925	24	18	Sequence 100.0, 18
29	100.0	925	24	18	Sequence 100.0, 18
30	100.0	925	24	18	Sequence 100.0, 18
31	100.0	925	24	18	Sequence 100.0, 18



















100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000



[illegible]

c	27	402.4	58.5	52.1	4	US-10-124-604-1B	US-10-124-604-1B
c	28	278.4	56.9	412	6	US-10-146-502-164	US-10-146-502-164
c	29	223.8	42.6	245	4	US-10-113-802-410	US-10-113-802-410
c	30	222	42.4	296	6	US-10-114-604-92	US-10-114-604-92
c	31	197.6	37.6	576	6	US-10-139-920-101B	US-10-139-920-101B
c	32	197.6	37.6	576	6	US-10-139-920-101B	US-10-139-920-101B
c	33	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	34	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	35	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	36	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	37	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	38	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	39	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	40	136	37.3	486	6	US-10-139-920-101B	US-10-139-920-101B
c	41	130	46.2	201	6	US-10-139-920-101B	US-10-139-920-101B
c	42	188.8	46.9	211	4	US-10-112-604-429	US-10-112-604-429
c	43	188.8	46.9	420	5	US-10-106-502-243	US-10-106-502-243
c	44	186.6	45.5	896	6	US-10-106-502-243	US-10-106-502-243
c	45	165.4	41.5	64	6	US-10-146-502-170.1	US-10-146-502-170.1

AL GUNNEN'S

AL GUNNEN'S

c	27	402.4	58.5	52.1	4	US-10-124-604-1B	US-10-124-604-1B
c	28	278.4	56.9	412	6	US-10-146-502-164	US-10-146-502-164
c	29	223.8	42.6	245	4	US-10-113-802-410	US-10-113-802-410
c	30	222	42.4	296	6	US-10-114-604-92	US-10-114-604-92
c	31	197.6	37.6	576	6	US-10-139-920-101B	US-10-139-920-101B
c	32	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	33	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	34	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	35	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	36	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	37	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	38	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	39	197.6	37.6	576	4	US-10-139-920-101B	US-10-139-920-101B
c	40	136	37.3	486	6	US-10-139-920-101B	US-10-139-920-101B
c	41	130	46.2	201	6	US-10-139-920-101B	US-10-139-920-101B
c	42	188.8	46.9	211	4	US-10-112-604-429	US-10-112-604-429
c	43	188.8	46.9	420	5	US-10-106-502-243	US-10-106-502-243
c	44	186.6	45.5	896	6	US-10-106-502-243	US-10-106-502-243
c	45	165.4	41.5	64	6	US-10-146-502-170.1	US-10-146-502-170.1

AL GUNNEN'S

AL GUNNEN'S

c	27	402.4	58.5	52.1	4	US-10-124-604-1B	US-10-124-604-1B
c	28	278.4	56.9	412	6	US-10-146-502-164	US-10-146-502-164
c	29	223.8	42.6	245	4	US-10-113-802-410	US-10-113-802-410
c	30	222	42.4	296	6	US-10-114-604-92	US-10-114-604-92
c	31	197.6	37.6	576	6	US-10-139-920-	

---

```

sequence 18, Appl
sequence 27, Appl
sequence 2118, Ap
sequence 1281, Ap
sequence 199, App
sequence 1635, Ap
sequence 1281, Ap
sequence 40, Appl
sequence 64, Appl
sequence 1331, Ap
sequence 2200, Ap
sequence 78, Appl
sequence 1463, Ap
sequence 1433, Ap
sequence 1231, Ap
sequence 1771, Ap
sequence 2131, Ap
sequence 6864, Ap
sequence 915, App
sequence 282, App
sequence 1486, Ap
sequence 1476, Ap
sequence 31, App

```

[illegible][illegible][illegible]













QY 303 gcaagagcaatcttctctcaatctctatctatgaagacacatgaagacacacattctctcc 460  
 bb 313 gcaagacacattctctctcaatctctatctatgaagacacacacacacacattctctcc 472  
 QY 361 gataagcaatctatcccacacatctatcttctgaacacacatctgaacatctatgaacacat 420  
 bb 373 gataagcaatctatcccacacatctatcttctgaacacacacacacacacacacacacacac 432  
 QY 423 atcactgaacacatctatgaac 480  
 bb 433 atcactgaacacatctatgaac 492  
 QY 481 ctctgaac 525  
 bb 493 caac 537

RESULT 15  
 US-10-146-502 1363/c  
 ? Sequence 1363, Application US/10146502  
 ? GENERAL INFORMATION:  
 ? APPLICANT: Jiang, Yuqin  
 ? APPLICANT: Harlocker, Susan L.  
 ? APPLICANT: Serfling, Heather  
 ? APPLICANT: Wang, Aijun  
 ? APPLICANT: Stolk, John A.  
 ? TITLE OF INVENTION: COMBINATIONS AND METHODS FOR THE THERAPY  
 ? FILE REFERENCE: 210121.92752  
 ? CURRENT APPLICATION NUMBER: US/10146-502  
 ? CURRENT FILING DATE: 2002-05-14  
 ? NUMBER OF SEQ IDS: 2241  
 ? SOFTWARE: FastSeq for Windows Version 4.0  
 ? SEQ ID NO 1463  
 ? LENGTH: 585  
 ? TYPE: DNA  
 ? ORGANISM: Homo sapiens  
 US-10-146-502-1463

Query Match 76.0% Score 400.43 Db 63 Length 585  
 Best Local Similarity 99.0% Prod. No. 1-6e-111  
 Matches 404 Conservative 0 Mismatches 4 Indels 0 Gaps 0

QY 119 tcccac 178  
 bb 585 tcccac 526  
 QY 179 aagctctctatataatctgaac 238  
 bb 525 aagctctctatataatctgaac 466  
 QY 239 aatgac 298  
 bb 465 aatgac 406  
 QY 299 tgaac 358  
 bb 405 tgaac 346  
 QY 359 ctgac 418  
 bb 345 ctgac 286  
 QY 419 atatcactgaac 478  
 bb 285 atatcactgaac 226  
 QY 474 tctctgaac 525  
 bb 225 tctctgaac 179

Search completed: July 19, 2002, 04:14:44  
 Job time: 1926 sec



us-09-254-760a-18.rnpn

0:27:33 2002

Fri

The first part of the paper discusses the importance of the study of the history of the United States. It is argued that the study of history is essential for a full understanding of the present. The second part of the paper discusses the importance of the study of the history of the United States. It is argued that the study of history is essential for a full understanding of the present. The third part of the paper discusses the importance of the study of the history of the United States. It is argued that the study of history is essential for a full understanding of the present.

[illegible][illegible]





















us-09-254-760a-18.rst

10:27:33 2002

Fri





























100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200





























































































THESE INFORMATIONS: 1. A, T, S, R, I ;  
US (9-602) 4HA 40

Country Match	74.08%	Score: 640,80	DB: 5;	Length: 778;
Best Local Similarity	98.88%	Prod. No.: 1,50150;		

[illegible]

```

RESULT 7
: US 10 146-502 1638
: Sequence 1638, Application US/10146502
: GENERAL INFORMATION:
: APPLICANT: Jiang, Yuhu
: APPLICANT: Bartelker, Susan L.
: APPLICANT: Seckist, Heather
: APPLICANT: Wang, Aijun
: APPLICANT: Stock, John A.
: TITLE OF INVENTOR: COMPOSITION AND
: TITLE OF INVENTOR: ANALYSIS OF
: FILE REFERENCE: 216121, 59762
: CURRENT APPLICANT NUMBER: 09113110
: CURRENT FILING DATE: 2002-05-14
: NUMBER OF SEQ. TO NEST: 2241
: SOFTWARE: FASTSEQ for WindowsVersion

```

: SETU TO NO. 26, 35  
 : LUNN III: 5, 50  
 : FYE: DNA  
 : REFINISM: H: 300; S: 100.5  
 JS-10 146.502 16.35

Query Match	67.88%	Score: 586.8	DB: 6	Length: 590
Best Local Similarity	99.78%	Prod. No.: 3,800	347	

[illegible]

```

RESULT      B
US 10 146 502 1363/-
? RECIPIENT 1363, APPLICATION 9510146502
? GENERAL INFORMATION:
? APPLICANT: Huang, Yuh-9
? APPLICANT: Bartolotti, Susan L.
? APPLICANT: Societati, Heather
? APPLICANT: Wind, Aijun
? APPLICANT: Stork, John A.
? TITLE OF INVENTION: CRYSTALLINE AND BLENDED POLYMER FILMS FOR THE THERAPY
? TITLE OF INVENTION: AND GLASS SUBSTRATE CANCER
? FILE REFERENCE: 21012132702
? CURRENT APPLICATION NUMBER: 02/02146502
? CURRENT FILING DATE: 2002-05-14
? REMARK: SEQ ID NO: 224
? SOFTWARE: FASTSEQ FOR WINDOWS Version 4.1.0
? SEQ ID NO: 1363
? LENGTH: 535
? TYPE: DNA
? ANNOTATION: Homo sapiens
? S: 10-146 502 1363

```







Fri Jul 19 10:27:35 2002

us-09-254-760a-27.rnpn

---

Page 10



[illegible][illegible][illegible][illegible]



XX  
AC  
XX  
14 16 JAN 2000 (first entry)  
XX  
DE Secreted protein (new) A1 P1  
XX  
KW Secreted protein (new) A1 P1  
KW chromosomal mutation (new) A1 P1  
KW hypolipidemia (new) A1 P1  
KW autoimmune disease (new) A1 P1  
KW renal failure (new) A1 P1  
XX  
OS Homo sapiens  
XX  
IN W 946469 A2  
XX  
15 12 AUG 1999  
XX  
16 09 FEB 1999 (new) P10262  
XX  
17 09 FEB 1999 (new) P10262  
XX  
18 13 APR 1999 (new) P10262  
XX  
19 13 APR 1999 (new) P10262  
XX  
20 04 SEP 1998 (new) P10262  
XX  
21 (new) P10262  
XX  
22 biochemistry (new) A1 P1  
XX  
23 WPI: 1999 00000/1  
XX  
24 N-TERM: AA74-98  
XX  
25 Extended cDNAs used for expression of secreted proteins and specific antibodies  
XX  
26 Claim 1: (new) 244pp: P10262  
XX  
27 This sequence represents a human secreted protein (new) A1 P1  
28 the extended cDNAs (for detection of secreted proteins) may be used for  
29 positive identification by DNA sequencing. These are useful for forensic identification  
30 alternative identification of secreted proteins. They may also be used for  
31 protein expression by the extended cDNAs as well as identification of secreted  
32 soluble proteins. The sequences can be used for chromosomal mapping and  
33 identification of genes associated with hereditary diseases of diet  
34 response, similar sequences that the cDNAs can be used for identification  
35 secreted proteins. Other sequences derived from the extended cDNAs may be  
36 used to create upstream genomic DNA sequences for identification of secreted  
37 proteins. Some of the proteins may be used for identification and treatment  
38 several disorders including, but not limited to, cancer, hypertension,  
39 cardiovascular and neurodegenerative diseases, and immune diseases and  
40 the metabolic diseases, endocrine diseases, diseases of the immune system,  
41 amino acid metabolism, hypolipidemia, and other related disorders.  
42 Sequence: (new) AA:  
XX  
SQ  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

XX  
AC  
XX  
14 16 JAN 2000 (first entry)  
XX  
DE Secreted protein (new) A1 P1  
XX  
KW Secreted protein (new) A1 P1  
KW chromosomal mutation (new) A1 P1  
KW hypolipidemia (new) A1 P1  
KW autoimmune disease (new) A1 P1  
KW renal failure (new) A1 P1  
XX  
OS Homo sapiens  
XX  
IN W 946469 A2  
XX  
15 12 AUG 1999  
XX  
16 09 FEB 1999 (new) P10262  
XX  
17 09 FEB 1999 (new) P10262  
XX  
18 13 APR 1999 (new) P10262  
XX  
19 13 APR 1999 (new) P10262  
XX  
20 04 SEP 1998 (new) P10262  
XX  
21 (new) P10262  
XX  
22 biochemistry (new) A1 P1  
XX  
23 WPI: 1999 00000/1  
XX  
24 N-TERM: AA74-98  
XX  
25 Extended cDNAs used for expression of secreted proteins and specific antibodies  
XX  
26 Claim 1: (new) 244pp: P10262  
XX  
27 This sequence represents a human secreted protein (new) A1 P1  
28 the extended cDNAs (for detection of secreted proteins) may be used for  
29 positive identification by DNA sequencing. These are useful for forensic identification  
30 alternative identification of secreted proteins. They may also be used for  
31 protein expression by the extended cDNAs as well as identification of secreted  
32 soluble proteins. The sequences can be used for chromosomal mapping and  
33 identification of genes associated with hereditary diseases of diet  
34 response, similar sequences that the cDNAs can be used for identification  
35 secreted proteins. Other sequences derived from the extended cDNAs may be  
36 used to create upstream genomic DNA sequences for identification of secreted  
37 proteins. Some of the proteins may be used for identification and treatment  
38 several disorders including, but not limited to, cancer, hypertension,  
39 cardiovascular and neurodegenerative diseases, and immune diseases and  
40 the metabolic diseases, endocrine diseases, diseases of the immune system,  
41 amino acid metabolism, hypolipidemia, and other related disorders.  
42 Sequence: (new) AA:  
XX  
SQ  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

















Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796

Sequence 2, Application US/99/06796















07 140 DI ----- DRYSNRLVAVEDAD 157  
11 11 11 11 11 11 11 11 11 11  
06 410 DILKAAIAAGSVSHVSAWASAS 435

Search completed: July 18, 2002, 10:20:41  
Job time: 122 sec

































Pending Nucleic Acid and/or Pending Amino Acid database searches now generate two sets of results. These databases were split into two parts to reduce the time needed to update the databases daily. The split freed up more machine time for processing searches.

Searches run against the Nucleic Acid Pending database produce two sets of results, with the extensions, **.rnpm** and **.rnpn**

Searches run against the Amino Acid Pending database produce two sets of results, with the extensions, **.rapm** and **.rapn**

*The Pending database search results should not be left in the case because they contain data that is confidential.*

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

1 NAME  
2 ADDRESS  
3 CITY  
4 STATE  
5 ZIP  
6 NAME  
7 ADDRESS  
8 CITY  
9 STATE  
10 ZIP  
11 NAME  
12 ADDRESS  
13 CITY  
14 STATE  
15 ZIP  
16 NAME  
17 ADDRESS  
18 CITY  
19 STATE  
20 ZIP  
21 NAME  
22 ADDRESS  
23 CITY  
24 STATE  
25 ZIP  
26 NAME  
27 ADDRESS  
28 CITY  
29 STATE  
30 ZIP  
31 NAME  
32 ADDRESS  
33 CITY  
34 STATE  
35 ZIP  
36 NAME  
37 ADDRESS  
38 CITY  
39 STATE  
40 ZIP  
41 NAME  
42 ADDRESS  
43 CITY  
44 STATE  
45 ZIP  
46 NAME  
47 ADDRESS  
48 CITY  
49 STATE  
50 ZIP  
51 NAME  
52 ADDRESS  
53 CITY  
54 STATE  
55 ZIP  
56 NAME  
57 ADDRESS  
58 CITY  
59 STATE  
60 ZIP  
61 NAME  
62 ADDRESS  
63 CITY  
64 STATE  
65 ZIP  
66 NAME  
67 ADDRESS  
68 CITY  
69 STATE  
70 ZIP  
71 NAME  
72 ADDRESS  
73 CITY  
74 STATE  
75 ZIP  
76 NAME  
77 ADDRESS  
78 CITY  
79 STATE  
80 ZIP  
81 NAME  
82 ADDRESS  
83 CITY  
84 STATE  
85 ZIP  
86 NAME  
87 ADDRESS  
88 CITY  
89 STATE  
90 ZIP  
91 NAME  
92 ADDRESS  
93 CITY  
94 STATE  
95 ZIP  
96 NAME  
97 ADDRESS  
98 CITY  
99 STATE  
100 ZIP

101 NAME  
102 ADDRESS  
103 CITY  
104 STATE  
105 ZIP  
106 NAME  
107 ADDRESS  
108 CITY  
109 STATE  
110 ZIP  
111 NAME  
112 ADDRESS  
113 CITY  
114 STATE  
115 ZIP  
116 NAME  
117 ADDRESS  
118 CITY  
119 STATE  
120 ZIP  
121 NAME  
122 ADDRESS  
123 CITY  
124 STATE  
125 ZIP  
126 NAME  
127 ADDRESS  
128 CITY  
129 STATE  
130 ZIP  
131 NAME  
132 ADDRESS  
133 CITY  
134 STATE  
135 ZIP  
136 NAME  
137 ADDRESS  
138 CITY  
139 STATE  
140 ZIP  
141 NAME  
142 ADDRESS  
143 CITY  
144 STATE  
145 ZIP  
146 NAME  
147 ADDRESS  
148 CITY  
149 STATE  
150 ZIP  
151 NAME  
152 ADDRESS  
153 CITY  
154 STATE  
155 ZIP  
156 NAME  
157 ADDRESS  
158 CITY  
159 STATE  
160 ZIP  
161 NAME  
162 ADDRESS  
163 CITY  
164 STATE  
165 ZIP  
166 NAME  
167 ADDRESS  
168 CITY  
169 STATE  
170 ZIP  
171 NAME  
172 ADDRESS  
173 CITY  
174 STATE  
175 ZIP  
176 NAME  
177 ADDRESS  
178 CITY  
179 STATE  
180 ZIP  
181 NAME  
182 ADDRESS  
183 CITY  
184 STATE  
185 ZIP  
186 NAME  
187 ADDRESS  
188 CITY  
189 STATE  
190 ZIP  
191 NAME  
192 ADDRESS  
193 CITY  
194 STATE  
195 ZIP  
196 NAME  
197 ADDRESS  
198 CITY  
199 STATE  
200 ZIP



















```

QY 10 LLLVAVTAAATVAGGPTTATGSELETLGSGWLCORSTLLALRGSTN 69
DB 11 LLLVTSSEA LAF FFE LTLGSGWLTHTVSTEELELALFK 59
QY 70 FFMETRLHLEHRCALERVAAGRLALAL CIVLMLVETTRHLELGGAVR 129
DB 60 FFMVTRHLEHRCALERVAAGRLALAL CIVLMLVETTRHLELGGAVR 119
QY 129 MEVDSITVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGV 175
DB 129 MEVDSITVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAG 169

```

## RESULT 9

```

US-10-119-480-116
: Sequence 116, Application US/10119480
: GENERAL INFORMATION:
: APPLICANT: Baker, Kevin P.
: APPLICANT: Insectors, the Corporation, Mary
: APPLICANT: Galszski, Paul J.
: APPLICANT: Grimaldi, J. Christopher
: APPLICANT: Gurney, Austin J.
: APPLICANT: Smith, Victoria
: APPLICANT: Chapin, Jean-Christophe
: APPLICANT: Watanabe, Colin L.
: APPLICANT: Wood, William
: TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
: FILE REFERENCE: ACIDS INCLUDING THE SAME
: CURRENT APPLICATION NUMBER: 05/10119480
: CURRENT FILING DATE: 2002-04-09
: NUMBER OF SEQ ID NOS: 246
: Error Application removed - See File Wrapper or Palm
: SEQ ID NO 116
: LENGTH: 166
: TYPE: PRT
: ORGANISM: Homo Sapien
US-10-119-480-116

```

```

Query Match 61.7%, Score 555, DB 6, Length 166,
Best Local Similarity 64.7%, Pred. No. 5, 6, 13,
Matches 106, Conservative 59, Mismatches 19, Gaps 4:

QY 10 LLLVAVTAAATVAGGPTTATGSELETLGSGWLCORSTLLALRGSTN 69
DB 11 LLLVTSSEA LAF FFE LTLGSGWLTHTVSTEELELALFK 59
QY 70 FFMETRLHLEHRCALERVAAGRLALAL CIVLMLVETTRHLELGGAVR 129
DB 60 FFMVTRHLEHRCALERVAAGRLALAL CIVLMLVETTRHLELGGAVR 119
QY 129 MEVDSITVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGV 175
DB 129 MEVDSITVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAG 169

```

## RESULT 10

```

PCT-US02-19669-204
: Sequence 204, Application PCT/US0219669
: GENERAL INFORMATION:
: APPLICANT: Millennium Pharmaceuticals, Inc., et al.
: TITLE OF INVENTION: COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT,
: PREVENTION, TREATMENT, AND THERAPY OF BREAST CANCER
: FILE REFERENCE: MRI-0388C
: CURRENT APPLICATION NUMBER: PCT/US0219669
: CURRENT FILING DATE: 2002-06-21
: PRIOR APPLICATION NUMBER: 05/60299, 997
: PRIOR FILING DATE: 2001-06-21
: PRIOR APPLICATION NUMBER: 05/60301, 572
: PRIOR FILING DATE: 2001-06-27

```

```

: PRIOR APPLICATION NUMBER: 05/607406, 503
: PRIOR FILING DATE: 2001-07-18
: PRIOR APPLICATION NUMBER: 05/607425, 002
: PRIOR FILING DATE: 2001-09-25
: PRIOR APPLICATION NUMBER: 05/607627, 535
: PRIOR FILING DATE: 2002-04-05
: PRIOR APPLICATION NUMBER: 05/607633, 832
: PRIOR FILING DATE: 2002-05-14
: NUMBER OF SEQ ID NOS: 506
: SEQ ID NO 204
: FEATURES: FEATURE 1: 101-166
: LENGTH: 167
: TYPE: PRT
: ORGANISM: Homo sapiens
PCT-US02-19669-204

```

```

Query Match 42.5%, Score 322, DB 17, Length 147,
Best Local Similarity 60.5%, Pred. No. 9, 20, 41,
Matches 71, Conservative 29, Mismatches 14, Gaps 4:

```

```

QY 10 LLLVAVTAAATVAGGPTTATGSELETLGSGWLCORSTLLALRGSTN 69
DB 11 LLLVTSSEA LAF FFE LTLGSGWLTHTVSTEELELALFK 59
QY 70 FFMETRLHLEHRCALERVAAGRLALAL CIVLMLVETTRHLELGGAVR 129
DB 60 FFMVTRHLEHRCALERVAAGRLALAL CIVLMLVETTRHLELGGAVR 119
QY 129 MEVDSITVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAG 175
DB 129 MEVDSITVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAGVAG 169

```

## RESULT 11

```

US-10-106-698-4511
: Sequence 4511, Application US/10106698
: GENERAL INFORMATION:
: APPLICANT: Rohan, et al.
: TITLE OF INVENTION: Colon and Colon Cancer Associated Polypeptides and Polypep
: FILE REFERENCE: PA00541
: CURRENT APPLICATION NUMBER: 05/106698
: CURRENT FILING DATE: 2002-01-27
: PRIOR APPLICATION NUMBER: 05/106624
: PRIOR FILING DATE: 2000-09-28
: PRIOR APPLICATION NUMBER: 05/607177, 117
: PRIOR FILING DATE: 1999-09-29
: PRIOR APPLICATION NUMBER: 05/607183, 280
: PRIOR FILING DATE: 1999-11-04
: NUMBER OF SEQ ID NOS: 8564
: FEATURES: FEATURE 1: 1-4511
: SEQ ID NO 4511
: LENGTH: 180
: TYPE: PRT
: ORGANISM: Homo sapiens
: FEATURE:
: NAME: KEY, MISC_FEATURE
: LOCATION: (6)
: OTHER INFORMATION: Xaa equals any of the naturally occurring L amino acids
: NAME: KEY, MISC_FEATURE
: LOCATION: (13)
: OTHER INFORMATION: Xaa equals any of the naturally occurring L amino acids
: NAME: KEY, MISC_FEATURE
: LOCATION: (15)
: OTHER INFORMATION: Xaa equals any of the naturally occurring L amino acids
US-10-106-698-4511

```

```

Query Match 40.2%, Score 361, DB 67, Length 180,
Best Local Similarity 59.7%, Pred. No. 1, 7, 28,
Matches 71, Conservative 22, Mismatches 14, Gaps 4:
QY 10 LLLVAVTAAATVAGGPTTATGSELETLGSGWLCORSTLLALRGSTN 69

```



```

1 SEQ ID NO: 25975
2 LENGTH: 909
3 TYPE: PRT
4 ORGANISM: Arabidopsis thaliana
5 FEATURE:
6 NAME/KEY: pep110
7 LOCATION: 1..906
8 OTHER INFORMATION: Genes: Sep. ID NO.: 3064209
9 US 09-045-625-25975

```

```

Query Match          9.98; Score 84.5; DB: ; Length 909;
Best Local Similarity 21.96; Prod. No. 8.62;
Matches 46; Conservative 41; Mismatches 76; Indels 53; Gaps 9;

07 5 PVSAFLLLVALSYLL-----ARETIVELGAEFI-----TESSEDELDTLSPPQWHLQDLWL 55
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
10 80 PQSQTLTFESSYSLQTFESSYSLQTFESSYSLQTFESSYSLQTFESSYSLQTFESSYSLQTF 137
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
07 56 QYVFAVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYV 107
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
10 148 EAEIVLREDELIVELVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLV 194
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
07 108 -----NLYVETTHILSPQGVYVR-----IMVVDLSLVRAHFI-- 141
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
10 195 VVNPESAVAHSLFESDEG--GVVSGTIFKSGDEGDEIRIVGVGLVGLVGLVGLVGLVGLV 251
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
07 142 -TPVYNNRYAYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYVYV 175
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
10 272 HEEAIEKATVAVVGLAVVLLHEETFEFIRKIRKAL 297

```

Search completed: July 18, 2002, 10:24:26  
Job Time: 217 sec









[illegible]

Query Match	9.2%	Score 82.91	Db 2:	Length 4487
Best Local Similarity	25.99%	14.1	Ref. 6.7%	
Matches	23	Conservative	17	Mismatches 35
				Indels 4
				Gaps 27

  

Q7	46	SPKFDQGLSGWMLQWLTVEEALYKFTKNEKLMITHRLEK	-	PASALAEKVFAP	93
		I I			
D6	26	SLEPLEAAHNSGPIVWMLVQATLQKPTKPT	-	PLNTSTGKTPYEVLES	84
		I I			
Q7	94	NKEIKOKLAEQVTLNLVY	-	AKP	111
		I I			
D6	85	PEFLKPKVQKLVVEVY	-	Y	102
		I I			

RESULT 10  
 C96607  
 disulfide bond isomerase [unpublished] Chlamydia pneumoniae (Strain J138)  
 C-Species: Chlamydia pneumoniae, Chlamydia pneumoniae  
 Clonote: 02\_Mar\_2001 sequence revision 02\_Mar\_2001 text change 02\_Mar\_2001  
 C-Accession: C86607  
 R-Accession: M1\_HIRAKAWA\_H; KIMURA\_M; TABUCHI\_M; KISHI\_T; TABUCHI\_K; SHIBATA\_T; KISHI\_T  
 Nucleic Acids Res. 28, 2411-2414, 2000  
 A-Title: Comparison of whole genome sequences of Chlamydia pneumoniae J138.  
 A-Reference number: A66431; M111; 2034049  
 A-Accession: C86607  
 A-Status: preliminary  
 M-Molecule type: DNA

[illegible]



















[illegible]

1. The first group of authors (e.g., [1, 2]) has shown that the use of the method of least squares for the determination of the parameters of the model is not efficient. The reason for this is that the model is nonlinear with respect to the parameters. The authors of [1, 2] have proposed the use of the method of least squares for the determination of the parameters of the model. The reason for this is that the model is nonlinear with respect to the parameters. The authors of [1, 2] have proposed the use of the method of least squares for the determination of the parameters of the model.

[illegible][illegible]

YOUNG LADS FAMILY

statement is not repeated, hence by and for comparison purposes, the above statement is not repeated.

[illegible]

Figure 1. The effect of the number of trials on the number of correct responses. The number of correct responses was significantly higher than the number of incorrect responses in all conditions. The number of correct responses was significantly higher than the number of incorrect responses in all conditions. The number of correct responses was significantly higher than the number of incorrect responses in all conditions.

Figure 1. The effect of the number of trials on the number of correct responses. The number of correct responses (Y-axis) is plotted against the number of trials (X-axis). The data points are connected by lines, and the error bars represent the standard error of the mean. The number of correct responses increases with the number of trials, reaching a plateau around 10 trials.

© 1997 by Blackwell Science Ltd  
Journal of Internal Medicine 241: 365–372

[illegible]



























1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity of the information.

2. The second section focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication channels, both internally and externally. The text suggests implementing regular meetings and reports to keep all stakeholders informed and aligned. It also discusses the benefits of open communication, such as improved collaboration and faster problem-solving.

3. The third part of the document addresses the challenges of managing a large and diverse team. It acknowledges that different team members may have varying skills, experiences, and backgrounds. The text provides strategies for fostering a cohesive team environment, such as providing training and development opportunities, encouraging cross-functional collaboration, and recognizing individual contributions. It also mentions the importance of setting clear expectations and roles for each team member.

4. The final section discusses the importance of innovation and continuous improvement. It states that organizations must constantly seek new ways to optimize their processes and services to remain competitive in a rapidly changing market. The text suggests encouraging a culture of innovation by rewarding creative ideas and allowing employees the freedom to experiment. It also mentions the importance of staying up-to-date with industry trends and technologies.